Myocardial changes after spironolactone in spontaneous hypertensive rats. A laser scanning confocal microscopy study

Leila Maria Meirelles Pereira1, C A Mandarim-de-Lacerda

  • 1Laboratory of Morphometry & Cardiovascular Morphology, Biomedical Centre, Institute of Biology, State University of Rio de Janeiro, Brazil.

Insights

Spironolactone alone had limited effects on cardiac structure in hypertensive rats. Combining spironolactone with enalapril or verapamil significantly improved myocardial structure and reduced fibrosis.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Histopathology

Background:

  • Spontaneously hypertensive rats (SHR) exhibit cardiac hypertrophy and fibrosis.
  • Spironolactone is a mineralocorticoid receptor antagonist with potential cardioprotective effects.
  • Combination therapies are often used to manage hypertension and its cardiac complications.

Purpose of the Study:

  • To evaluate the effects of spironolactone monotherapy and combination therapy on cardiac structure in SHR.
  • To investigate the dose-dependent effects of spironolactone on blood pressure and myocardial alterations.
  • To compare the efficacy of spironolactone combined with enalapril or verapamil against monotherapy.

Main Methods:

  • Laser scanning confocal microscopy was used to assess cardiac structure.
  • Thirty spontaneously hypertensive rats were divided into six treatment groups over 13 weeks.
  • Treatments included control, varying doses of spironolactone, spironolactone + enalapril, and spironolactone + verapamil.

Main Results:

  • Spironolactone demonstrated a dose-dependent effect on blood pressure.
  • High-dose spironolactone or combination therapy with enalapril partially prevented cardiac hypertrophy.
  • Spironolactone monotherapy showed limited improvement, with persistent cardiac myocyte hypertrophy, fibrosis, and inflammation.
  • Combination therapy with enalapril or verapamil effectively prevented myocardial structural alterations.

Conclusions:

  • Spironolactone monotherapy offers limited cardioprotection against structural damage and fibrosis in SHR.
  • Combining spironolactone with enalapril or verapamil enhances its efficacy in preserving myocardial structure.
  • Combination therapy is a more effective strategy for mitigating cardiac remodeling in this hypertensive model.

Related Concept Videos